Business Development - XOMA Royalty has completed acquisitions of Turnstone Biologics and HilleVax, and announced acquisitions of LAVA Therapeutics and Mural Oncology [1][6] - The company acted as a structuring agent for XenoTherapeutics' acquisition of ESSA Pharma [1] Key Pipeline Advancements - Zevra Therapeutics submitted a Marketing Authorization Application (MAA) for arimoclomol to treat Niemann-Pick Type C [2] - Rezolute Bio expects to announce topline data in December from its Phase 3 ersodetug trial for congenital hyperinsulinism [2] - Gossamer Bio anticipates topline results from its Phase 3 trial of seralutunib in pulmonary atrial hypertension in February 2026 [2] Financial Performance - In the first nine months of 2025, XOMA Royalty received $43.9 million in royalties and milestones, with $14.3 million received in the third quarter [3][10] - Income for the three and nine months ended September 30, 2025, was $9.4 million and $38.4 million, respectively, compared to $7.2 million and $19.8 million for the same periods in 2024 [10] - Net income for the three and nine months ended September 30, 2025, was $14.1 million and $25.6 million, compared to net losses of $17.2 million and $9.9 million in the corresponding periods of 2024 [17] Cash Position - As of September 30, 2025, XOMA Royalty had cash and cash equivalents of $130.6 million, including $85.4 million in restricted cash [18][19] - The company received $14.3 million in cash receipts from royalties and commercial payments in the third quarter of 2025 [20] Acquisitions and Royalty Interests - XOMA Royalty will secure economic interests in partnered assets from LAVA Therapeutics, including PF-08046052 and JNJ-89853413 [5] - The acquisition of Mural Oncology is expected to close in the fourth quarter of 2025, with cash payments ranging from $2.035 to $2.24 per share [6] Research and Development Expenses - R&D expenses for the three and nine months ended September 30, 2025, were $69 thousand and $1.4 million, respectively [11] - The increase in R&D expenses in 2025 was primarily related to clinical trial costs following the acquisition of Kinnate [11] General and Administrative Expenses - G&A expenses for the three and nine months ended September 30, 2025, were $9.7 million and $25.7 million, respectively [12] - The increase in G&A expenses for the three months ended September 30, 2025, was due to higher business development costs [12]

Core Viewpoint - LAVA Therapeutics N.V. is urging its shareholders to tender their shares in the ongoing acquisition offer from XOMA Royalty Corporation before the expiration deadline of November 12, 2025, to avoid potential risks associated with the failure of the transaction [1][3][12]. Group 1: Transaction Details - On August 4, 2025, LAVA and XOMA entered into a share purchase agreement, with XOMA extending its offer to purchase all outstanding common shares of LAVA until November 12, 2025 [2]. - The LAVA Board unanimously recommends that shareholders tender their shares to ensure the completion of the offer [3]. Group 2: Risks of Non-Completion - If the requisite percentage of shares is not tendered, the offer cannot be completed, which may lead to significant risks for shareholders, including potential liquidation and dissolution of LAVA [3][6]. - In the event of non-completion, LAVA's share price may decline, particularly if the current market price reflects expectations of the offer being completed [6]. Group 3: Share Tendering Process - Shareholders holding LAVA shares through brokers are advised to instruct their brokers to tender their shares promptly to meet processing deadlines [4][5]. - Those who have previously tendered their shares do not need to take any further action due to the extension of the offer [8]. Group 4: Company Overview - LAVA Therapeutics is a biopharmaceutical company focused on developing bispecific gamma delta T cell engagers using its proprietary Gammabody® platform, with partnerships including Johnson & Johnson and Pfizer [9].

Core Points - Mural Oncology plc's shareholders approved the acquisition by XRA 5 Corp, a subsidiary of XOMA Royalty Corporation, with over 99% of votes in favor at both the Scheme Meeting and Extraordinary General Meeting held on October 24, 2025 [1][4][10] Acquisition Details - The acquisition agreement stipulates that Mural shareholders will receive a base cash price of $2.035 per share, based on an estimated closing net cash of approximately $36.2 million [2][3] - The total value of Mural's issued share capital is approximately $36.2 million, excluding any additional cash that may be payable [3] - The acquisition is expected to close in the fourth quarter of 2025, pending customary closing conditions and approval from the High Court of Ireland [3] Voting Results - At the Scheme Meeting, 10,103,706 shares (99.20%) voted in favor of the proposal, representing 58.31% of the total shares outstanding [8][9] - At the EGM, 10,607,228 shares (99.16%) approved the proposal, with 10,647,967 shares (99.54%) voting in favor of the amendment to the articles of association [10][10]

Core Points - XOMA Royalty Corporation and LAVA Therapeutics N.V. have amended their definitive share purchase agreement, adjusting the cash amount and contingent value rights for LAVA shareholders [1][2] Summary by Sections Amendment Details - LAVA shareholders will now receive an initial cash amount of $1.04 per share, down from the previously agreed range of $1.16 to $1.24 [2] - The non-transferable contingent value right (CVR) will allow shareholders to receive 75% of net proceeds from LAVA's partnered assets and any net proceeds from unpartnered programs, plus a potential additional $0.23 per CVR based on certain liabilities [2] - The minimum net-cash closing condition has been reduced to $24.5 million from $31.5 million [2] Offer Extension - The tender offer expiration has been extended to November 12, 2025, from the original date of October 17, 2025 [3] - The acquisition is expected to close in the fourth quarter of 2025, pending customary closing conditions [3] Shareholder Actions - Shareholders who have already tendered their shares do not need to take further action due to the extension [4] - Support agreements have been signed by LAVA shareholders to tender their shares before the new expiration date [4] Closing Conditions - The closing of the offer is contingent upon the tender of at least 80% of LAVA's outstanding shares, adoption of certain resolutions at the shareholder meeting, and maintaining a minimum net-cash balance [5] Extraordinary General Meeting - LAVA will reconvene its Extraordinary General Meeting of Shareholders on November 7, 2025, to approve matters related to the transaction [6]

Group 1 - The focus is on income-producing asset classes such as REITs, ETFs, Preferreds, and 'Dividend Champions' that target premium dividend yields up to 10% [1] - iREIT®+HOYA Capital is highlighted as a premier income-focused investing service that offers sustainable portfolio income, diversification, and inflation hedging opportunities [2] - XOMA Royalty Corporation provides preferred stock investors with a chance to diversify their holdings away from mREITs and banks without needing to invest in ETFs or CEFs [3]

Group 1 - The focus is on income-producing asset classes such as REITs, ETFs, Preferreds, and 'Dividend Champions' that target premium dividend yields up to 10% [1] - iREIT®+HOYA Capital is highlighted as a premier income-focused investing service that offers sustainable portfolio income, diversification, and inflation hedging opportunities [2] - XOMA Royalty Corporation provides preferred stock investors a chance to diversify their holdings away from mREITs and banks without needing to invest in ETFs or CEFs [3]

Group 1 - The article does not provide any specific information or data regarding companies or industries [1]

Core Points - XOMA Royalty Corporation has extended its tender offer to purchase all outstanding shares of LAVA Therapeutics N.V. until October 17, 2025, with the acquisition expected to close in Q4 2025 [1][2] Group 1: Tender Offer Details - The tender offer includes a cash amount and a non-transferable contingent value right (CVR) per share, entitling shareholders to 75% of net proceeds from LAVA's partnered assets and any out-licensed or sold unpartnered programs [1] - LAVA shareholders who have already tendered their shares do not need to take further action due to the extension of the offer [3] - The closing of the offer is contingent upon the tender of at least 80% of LAVA's outstanding shares, adoption of certain resolutions by LAVA's shareholders, and other customary closing conditions [4] Group 2: Company Background - XOMA Royalty is a biotechnology royalty aggregator that acquires future economic rights associated with therapeutic candidates licensed to pharmaceutical companies, providing non-dilutive funding to sellers [5] - LAVA Therapeutics is a biopharmaceutical company focused on developing bispecific gamma delta T cell engagers using its proprietary Gammabody® platform, with partnerships with Johnson & Johnson and Pfizer [6][7]

Core Viewpoint - Mural Oncology plc has published a definitive proxy statement regarding its acquisition by XOMA Royalty Corporation, which is set to be voted on by shareholders in an upcoming meeting [1][2][3]. Group 1: Acquisition Details - The acquisition involves XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty, acquiring the entire issued share capital of Mural through a scheme of arrangement sanctioned by the Irish High Court [2]. - The Proxy Statement includes essential information for Mural shareholders, such as the terms and conditions of the acquisition, voting instructions, and necessary legal disclosures [3][12]. Group 2: Shareholder Meetings - A scheme meeting for Mural shareholders is scheduled for October 24, 2025, at 10:30 a.m. Irish local time, followed by an extraordinary general meeting at 10:45 a.m. [6]. - Both meetings will take place at Ten Earlsfort Terrace, Dublin, Ireland [6]. Group 3: Company Background - Mural Oncology is a biotechnology company focused on developing cytokine-based immunotherapies for cancer treatment [7]. - The company has faced challenges, including the discontinuation of its nemvaleukin development after failing to meet primary endpoints in clinical trials [8].

Group 1 - XOMA Royalty's shares have increased by 14.8% in the past four weeks, closing at $37.59, with a mean price target of $69.67 indicating a potential upside of 85.3% [1] - The mean estimate includes three short-term price targets with a standard deviation of $29.84, where the lowest estimate suggests a 33% increase to $50.00, and the highest estimate predicts a surge of 176.7% to $104.00 [2] - Analysts show strong agreement on XOMA's ability to report better earnings, with a positive trend in earnings estimate revisions correlating with potential stock price increases [4][11] Group 2 - The Zacks Consensus Estimate for XOMA's current year earnings has risen by 45.5% over the past month, with no negative revisions [12] - XOMA holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting exact gains, they can provide a directional guide for price movement [14]